16/08/19	Viscogliosi Brothers LLC cancelled the acquisition of OP-1 Portfolio Program from Ember Therapeutics, Inc..	CI
16/08/18	Viscogliosi Brothers LLC entered into a letter of intent to acquire OP-1 Portfolio Program from Ember Therapeutics, Inc..	CI
08/09/16	Ember Therapeutics, Inc. acquired the assets of of Dermasilk Brands, Inc. from Midwood Distributors, Inc. for $1.3 million.	CI
06/07/16	Knight Therapeutics Inc. and Ember Therapeutics, Inc. Expand Distribution Partnership	CI
21/03/16	Ember Therapeutics, Inc. entered into a definitive agreement to acquire the assets of Migralex, Inc. for $0.87 million.	CI
16/03/16	Ember Therapeutics, Inc. acquired ICX-RHY/Vavelta from Intercytex Limited for $1.1 million.	CI
24/02/16	American Home Alliance Corp will Change its Ticker to EMBT from AHLL	CI
24/02/16	AMERICAN HOME ALLIANCE CORP will Change its Name to Ember Therapeutics, Inc	CI
03/02/16	Ember Therapeutics, Inc. acquired American Home Alliance Corp. in a reverse merger transaction.	CI
19/10/15	Ember Therapeutics, Inc. Announces Initial Positive Results from a Phase 2 Trial of BMP-7	CI
12/03/15	Mariel Therapeutics, Inc. acquired Ember Therapeutics, Inc. from Third Rock Ventures II, L.P. of Third Rock Ventures II, L.P. and others for $6 million.	CI
31/12/14	Ember Therapeutics, Inc. acquired Worldwide License of BMP-7 and OP-1 Portfolio from Stryker Corporation.	CI
27/09/12	Ember Therapeutics, Inc. Announces Publication of Key Preclinical Data Demonstrating Inhibition of Transient Receptor Potential Vanilloid	CI

29/05/22	Alternative Liquidity Index LP Announces an Extension of the Tender Offer for Ember Therapeutics, Inc.	AQ
18/11/21	Moore Kuehn Encourages EMBT, VSAT, IHC and CSPR Investors to Contact Law Firm	PR

Company Profile

Employees

Sector